↓ Skip to main content

Teriflunomide for multiple sclerosis

Overview of attention for article published in this source, December 2012
Altmetric Badge

Mentioned by

2 tweeters
6 Wikipedia pages
1 research highlight platform


24 Dimensions

Readers on

100 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Teriflunomide for multiple sclerosis
Published by
John Wiley & Sons, Ltd, December 2012
DOI 10.1002/14651858.cd009882.pub2
Pubmed ID

He, Dian, Xu, Zhu, Dong, Shuai, Zhang, Hong, Zhou, Hongyu, Wang, Lu, Zhang, Shihong


Disease-modifying therapies (DMTs) for multiple sclerosis aim to specifically reduce inflammation in relapsing multiple sclerosis and promote neuroprotection and neurorepair in progressive multiple sclerosis (MS). Most of the currently available disease-modifying drugs (DMDs) require regular and frequent parenteral administration, which imposes a burden on patients and leads to reduced adherence. Not all MS patients respond adequately to current DMDs and, therefore, alternative MS treatments with less invasive routes of administration and new modes of action are required to expand the current treatment repertoire, increase adherence, and thereby improve efficacy. As one of the oral DMDs, teriflunomide is a potentially promising new oral agent in the treatment of relapsing MS. It inhibits dihydro-orotate dehydrogenase (DHODH) and the synthesis of pyrimidine and has selective immunosuppressive and immunomodulatory properties.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 100 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 2%
Brazil 2 2%
Spain 2 2%
Ireland 1 1%
Finland 1 1%
Unknown 92 92%

Demographic breakdown

Readers by professional status Count As %
Student > Master 17 17%
Student > Ph. D. Student 13 13%
Student > Bachelor 13 13%
Other 9 9%
Researcher 7 7%
Other 14 14%
Unknown 27 27%
Readers by discipline Count As %
Medicine and Dentistry 28 28%
Agricultural and Biological Sciences 7 7%
Nursing and Health Professions 6 6%
Neuroscience 6 6%
Pharmacology, Toxicology and Pharmaceutical Science 5 5%
Other 15 15%
Unknown 33 33%